skip to Main Content

Federal government awards the University of Toronto $114-million regenerative medicine grant

University of TorontoOn Tuesday, July 28, 2015, the federal government announced a $114-million grant to cement the University of Toronto‘s position as one of the world’s leading centres for the design and manufacture of cells, tissues and organs to treat degenerative disease.

This announcement was covered in The Globe & Mail and Lab Products News, and by CBC.ca, CTV News and Global TV. MaRS Innovation was specifically mentioned as a commercialization partner in the Toronto Star‘s coverage.

As the university’s commercialization agent, MaRS Innovation welcomes this news and the downstream companies and technology licenses it will create. The Honourable Ed Holder, Minister of State (Science and Technology), made the announcement.

The funding will allow U of T, in partnership with its research partners and fellow MI members — The Hospital for Sick Children, the University Health Network and Mount Sinai Hospital — to conduct transformational research and clinical translation in regenerative medicine, enhance capability in synthetic biology and computational biology and foster translation, commercialization and clinical impacts.

Continue Reading

MaRS Innovation collaborating with Johnson & Johnson Innovation and Janssen to advance Cardiac, Diabetes and Depression technologies

mi_logoTORONTO, Jan. 12, 2015  — MaRS Innovation, the commercialization agent for Ontario’s 15 leading academic institutions, today announced that it has formed a research collaboration with Johnson & Johnson Innovation, LLC and its Canadian affiliate, Janssen Inc., to advance three technologies focused on cardiac, diabetes and depression, respectively.

This announcement was covered in Lab Product News.

“These three projects reflect the quality of innovation present in Toronto’s research community for our industry partners, and Toronto’s progress in addressing healthcare issues of international concern,” said Dr. Raphael Hofstein, president and CEO of MaRS Innovation. “Johnson & Johnson Innovation is a long-term strategic partner of MaRS Innovation and of our members; our collaboration reflects the benefits to accessing our members’ deal flow through MaRS Innovation. Through these deals and other scientific exchanges, we see increased interest in Toronto’s innovation and entrepreneurship community.”

The projects’ principal investigators are researchers from the University Health Network (UHN), the Centre for Addiction and Mental Health (CAMH) and the University of Toronto. This announcement follows Johnson & Johnson Innovation’s December 2013 commitment to collaborate on early-stage drug development projects.

Continue Reading
Back To Top